Why the study?
Does the assessment of rare and common genetic variants improve hypertrophic cardiomyopathy risk prediction beyond clinical factors in the general population?
Does the assessment of rare and common genetic variants improve hypertrophic cardiomyopathy risk prediction beyond clinical factors in the general population?
Incorporating rare and common genetic variants improves the prediction of hypertrophic cardiomyopathy risk beyond standard clinical factors.
May enhance HCM risk stratification; hypothesis-generating and requires prospective validation before clinical adoption.
Both rare and common genetic variants contribute substantially to HCM susceptibility in the general population and improve HCM risk prediction beyond that achieved with clinical factors.
No takes yet. Share an insight, caveat, or question.
Biddinger et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: